Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.
about
Cellular proteostasis: degradation of misfolded proteins by lysosomesFBXO32, encoding a member of the SCF complex, is mutated in dilated cardiomyopathyEndocytosed 2-Microglobulin Amyloid Fibrils Induce Necrosis and Apoptosis of Rabbit Synovial Fibroblasts by Disrupting Endosomal/Lysosomal Membranes: A Novel Mechanism on the Cytotoxicity of Amyloid Fibrils.Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.Recent advances in the management of AL Amyloidosis.Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.LITTLE FISH, BIG DATA: ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR AND METABOLIC DISEASE.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases.Recent advances in the noninvasive strategies of cardiac amyloidosis.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Sulfated glycosaminoglycans in protein aggregation diseases.Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes.Rotenone Induces the Formation of 4-Hydroxynonenal Aggresomes. Role of ROS-Mediated Tubulin Hyperacetylation and Autophagic Flux Disruption.Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis.Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity.Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.The yin and yang of autophagy in AL amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis
P2860
Q28079032-434427AF-5C45-4A27-BAC3-AEF2A04EB278Q28116320-A8778B1D-2985-46E5-91DD-8B469415CBA3Q35793465-25DFA8EF-A184-4152-B5A3-FE9A372C8D40Q36115813-BDD647B8-482D-4D65-A63E-6C66EC68BA2FQ36325334-3FBAE50F-D700-44E1-BBF0-6C1C5F687CBAQ38613822-48641467-4D04-4A79-AAB7-F68C38E8F70BQ38663987-36C3B395-D2AE-485A-A91E-7CA7EF2ED603Q38806486-65E8750D-800D-4139-BF39-2471AEA3326BQ38851025-7D34240D-85A3-4628-B21B-3884513A3990Q38864723-53610194-5EC4-4C06-8EA2-A049190B0BC2Q38935425-251E8447-D21B-47E6-9268-79AB118DF131Q39024208-82F704DA-0D35-4452-B7D0-991549BBF0DFQ39236820-5DD42595-3F92-427A-A915-53B0ADE554EAQ41106816-A17E7FB4-3BAF-49E1-BB84-259D23D96825Q42038712-9A9A0579-56CF-4874-BBDC-F9D240A09706Q45291266-E1B4B8F3-3ADA-49C3-AE12-5FF015C2F5CBQ46194651-D7FF419B-8938-4B4B-A6BC-8D9F99F92D64Q46365967-62408592-2EDD-4672-A181-19CB1D76E151Q46426248-7C60435F-3493-467A-9E2C-DA1982E48990Q46463218-EAB2F3A8-D12F-4382-8B37-414118819628Q46619541-DD3356C8-BFFB-48DA-AC01-E17FFAABDE77Q47332537-8949CF56-D282-459C-9EDC-CFF039DBBF3CQ47404960-AFF52717-F8DE-43B8-9592-751839B98BDEQ48276758-4A0AF5CF-BF52-4A4D-BF06-686FB6B290EEQ57166910-E68CE880-7622-462B-9177-7439A5BF735A
P2860
Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@ast
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@en
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@nl
type
label
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@ast
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@en
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@nl
prefLabel
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@ast
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@en
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity.
@nl
P2093
P2860
P356
P1476
Lysosomal dysfunction and impa ...... chain-mediated cardiotoxicity
@en
P2093
Calum A MacRae
David C Seldin
Jianru Shi
Kyle Trudeau
Marc Liesa
Orian S Shirihai
Rodney H Falk
Ronglih Liao
P2860
P304
P356
10.15252/EMMM.201404190
P577
2014-11-01T00:00:00Z